Skip to main content
Skip to main navigation
Invalid credentials.
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical R&D
Biopharmaceutical Sales & Marketing
Biosimilars
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Cardiovascular
Central Nervous System
Diabetes & Endocrinology
Infectious Diseases
Internal Medicine
Oncology
Early Phase Oncology
Translational Oncology
Pediatrics
Public Health Interest
Vaccines
Other Therapeutic Areas
Our Focus
Our Values
Our Heritage
Our Leadership
Ethics & Compliance
Investors
Global Locations
United States
Phone:1-866-267-4479
Request a Proposal
Phone:0-800-89-0011
Phone:0-800-99-1011
Email:commercial.germany@quintiles.com
Phone:0621-84508-113
Phone:1-800-881-011
Email:info@quintiles.com
Phone:0-800-555-4288
Email:clinical@quintiles.at
Phone:0-800-200-288
Email:commercial.bd.be@quintiles.com
Phone:+32 2 555 05 55
Phone:0-800-890-0288
Phone:00-800-0010
Phone:+1 514 855 0888
Phone:800-225-288
Email:asia@quintiles.com
Phone:10-811
Phone:01-800-911-0010
Phone:0-800-011-4114
Phone:0800-220-111
Phone:00-800-222-55288
Phone:800-100-10
Phone:2-0102247-3804
Phone:800-12001
Phone:0-800-11-0015
Phone:191
Phone:00-800-1311
Phone:999-9190
Phone:800-96-1111
Phone:06-800-011-11
Phone:000-117
Phone:001-801-10
Phone:1-800-550-000
Phone:1-80-949-4949
Email:qmil.clinical@quintiles.com
Phone:800-172-444
Email:qjpn.corpmktg@quintiles.com
Phone:00-539-111
Phone:8000-2288
Phone:
Phone:1-800-80-0011
Phone:800-901-10
Phone:01-800-288-2872
Phone:+31 23 567 0910
Phone:000-911
Phone:800-190-11
Phone:800-0109
Phone:0-800-50-288
Phone:1010-5511-00
Email:QWAW.Reception@quintiles.com
Phone:0-0-800-111-1111
Phone:800-800-128
Phone:0808-03-4288
Phone:8^10-800-110-1011
Phone:800-011-1111
Phone:0-800-000-101
Phone:0-800-99-0123
Phone:900-99-0011
Email:info.sweden@quintiles.com
Phone:020-799-111
Email:info@outcome.com
Phone:0-800-890011
Phone:00-801-102-880
Phone:1-800-0001-33
Phone:0811-288-0001
Phone:0^00-11
Phone:1-201-0288
Facebook Twitter LinkedIn YouTube
It comprises the start up documentation submission to the competent authorities (State Agency of Medicines and Ethics Committee), site selection and assessment, study start up and monitoring according to the Study Protocol, data acquisition, summarization and forwarding to the Sponsor.All the studies conducted in Latvia are a part of international studies. The research is done in the assignment of pharmaceutical companies (e.g., a pharmaceutical company decides to carry out a research of a new or an existing product, and Ltd Quintiles Latvia performs the role of intermediary, coordinating the cooperation of pharmaceutical company with the medical enterprise by monitoring the study process).
There is a continuous cooperation and communication with the State Agency of Medicine, Ethics Committee. (All the documentation is prepared according the legislation and submitted in the above mentioned organizations). Employees of Ltd Quintiles Latvia perform regular visits to the Study sites (medical enterprises in Latvia).
Ltd Quintiles Latvia follows all the Quintiles Eastern Holdings GesmbH guidelines and policies. Study agreements are signed between Study sites or Investigators and Quintiles Eastern Holdings GesmbH. Ltd Quintiles Latvia employees are just monitoring the data management at the sites.
Clinical research in Latvia is stipulated by the Cabinet Regulation No 172 “Regulations on Conducting Clinical Trials and Non-interventional studies and Labelling of Investigational Medicinal Products, and Procedure for Conducting Inspections on Compliance with the Requirements of Good Clinical Practice” of 28 February 2006 (see:http://www.zva.gov.lv/doc_upl/MK-172-28022006-ENGv3.pdf) (Amendment to Regulation No 17 as of 15.01.2008.)
1. Clinical trials related European directives (also in Latvian), guidelines, application forms, „Q&A document” and other relevant information can be found on:http://www.eudract.eudra.org > Access to EudraCT Supporting Documentation > EudraLex Volume 10
2. Normative requirements for reporting of adverse drug reactions in clinical trials are defined in Cabinet Regulation No 172, 28 February 2006 "Regulations on Conducting Clinical Trials and Non-interventional studies and Labelling of Investigational Medicinal Products, and Procedure for Conducting Inspections on Compliance with the Requirements of Good Clinical Practice".
3. More detailed information on e-reporting of adverse drug reactions and E2B implementation status in Latvia can be found on:http://eudravigilance.emea.europa.eu/human/index.asp > E-Reporting to Member States > Latvia
4. Information about the activities of the Clinical Trial Facilitation Group (CTFG) established by EU Heads of Medicines Agencies and Voluntary Harmonization Procedure (VHP) for assessment of multicentre clinical trials can be found on: Guidance document for a Voluntary Harmonisation Procedure (VHP) for the assessment of multinational Clinical Trial Applications
Addittional information: http://www.zva.gov.lv/